Perspective: a program to improve protein biomarker discovery for cancer.

Biomarkers for cancer risk, early detection, prognosis, and therapeutic response promise to revolutionize cancer management. Protein biomarkers offer tremendous potential in this regard due to their great diversity and intimate involvement in physiology. An effective program to discover protein biomarkers using existing technology will require team science, an integrated informatics platform, identification and quantitation of candidate biomarkers in disease tissue, mouse models of disease, standardized reagents for analyzing candidate biomarkers in bodily fluids, and implementation of automation. Technology improvements for better fractionation of the proteome, selection of specific biomarkers from complex mixtures, and multiplexed assay of biomarkers would greatly enhance progress.

[1]  M. Widschwendter,et al.  Methylated DNA as a possible screening marker for neoplastic disease in several body fluids , 2003, Expert review of molecular diagnostics.

[2]  E. Perez,et al.  Future options with trastuzumab for primary systemic and adjuvant therapy. , 2004, Seminars in oncology.

[3]  A. Feinberg,et al.  Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk , 2003, Science.

[4]  R. Jirtle.  IGF2 loss of imprinting: a potential heritable risk factor for colorectal cancer. , 2004, Gastroenterology.

[5]  R. Aebersold,et al.  Proteomics: the first decade and beyond , 2003, Nature Genetics.

[6]  B. Reid,et al.  Focus on Barrett's esophagus and esophageal adenocarcinoma. , 2004, Cancer cell.

[7]  J. Radich,et al.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia , 2003, Current oncology reports.

[8]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[9]  Lajos Pusztai,et al.  Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.

[10]  J. Radich,et al.  Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. , 1995, Blood.

[11]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[12]  T. Paz-Elizur,et al.  DNA repair activity for oxidative damage and risk of lung cancer. , 2003, Journal of the National Cancer Institute.

[13]  S. Roberts,et al.  Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. , 1999, International journal of radiation biology.

[14]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Stram,et al.  Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[17]  Stephen Lam,et al.  Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers , 2003, International journal of cancer.

[18]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[19]  S. Winawer,et al.  Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. , 1995, Bulletin of the World Health Organization.

[20]  S. Winawer.  A quarter century of colorectal cancer screening: progress and prospects. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. L. Patrick,et al.  The current status of the Papanicolaou smear , 1995, CA: a cancer journal for clinicians.

[22]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[23]  R. Aebersold,et al.  Design and synthesis of visible isotope-coded affinity tags for the absolute quantification of specific proteins in complex mixtures. , 2004, Bioconjugate chemistry.

[24]  B. Druker.  Imatinib as a paradigm of targeted therapies , 2003 .

[25]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[26]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.